Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
The aim of the present study is to examine whether cerebral oxygenation could be a more useful parameter than peripheral oxygen saturation to guide clinical titration of permissive hypoxemia in COVID-19 ARDS patients
Description: Cardiovascular and pulmonary optimization: Step 0 = Baseline, Step 1 = Derecruitment, Step 2 = Recruitment, Step 3 = Norepinephrine challenge, Step 4 = FiO2 increase, Step 5 = FiO2 decrease, Step 6 = Baseline 2
Measure: Changes in cerebral oxygenation (ScO2) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in peripheral oxygen saturation (SatO2) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in systolic arterial pressure (SAP) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in diastolic arterial pressure (DAP) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in mean arterial pressure (MAP) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in heart rate (HR) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in stroke volume (SV) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in cardiac output (CO) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in systemic vascular resistance (SVR) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in peripheral perfussion index (PPI) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in pH during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in PaO2 during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in PaCO2 during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in arterial saturation (SaO2) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in PvO2 during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in PvCO2 during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in mixed venous saturation (SvO2) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in lacatate during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in hemoglobine concentration (Hb) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in muscular oxygenation (SmO2) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and peripheral oxygen saturation (SatO2) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and systemic arterial pressure (SAP) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and diastolic arterial pressure (DAP) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and mean arterial pressure (MAP) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and stroke volume (SV) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and heart rate (HR) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and cardiac output (CO) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and systemic vascular resistance (SVR) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and peripheral perfussion index (PPI) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and pH during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and PaO2 during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and PaCO2 during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and arterial saturation (SaO2) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and PvO2 during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and PvCO2 during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and mixed venous saturation (SvO2) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and lactate during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and hemoglobine concentration (Hb) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and muscular oxygenation (SmO2) during cardiovascular and pulmonary optimization Time: 1 hourAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports